Clinical Trial Update: Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating pegylated liposomal doxorubicin with carboplatin as first-line therapy for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN